Chinese General Practice ›› 2023, Vol. 26 ›› Issue (15): 1824-1830.DOI: 10.12114/j.issn.1007-9572.2022.0792
• Monographic Research of Inpatient Glucose Menitoring • Previous Articles Next Articles
Received:
2022-08-25
Revised:
2022-12-05
Published:
2023-05-20
Online:
2022-12-05
Contact:
HE Jidong
通讯作者:
何继东
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0792
文献 | 年轻的新诊断的糖尿病患者和低血糖风险小的患者 | 低血糖高危患者a | 使用糖皮质激素患者 | 重症监护室(ICU)非重症患者 | 特殊情况b |
---|---|---|---|---|---|
2017中国住院患者血糖管理专家共识[ | FPG:4.4~6.1 mmol/L,2 hPG或随机血糖6.1~7.8 mmol/L | FPG:7.8~10.0 mmol/L,2 hPG或随机血糖7.8~13.9 mmol/L | FPG:6.1~7.8 mmol/L,2 hPG或随机血糖,7.8~10.0 mmol/L | FPG:6.1~7.8 mmol/L,2 hPG或随机血糖7.8~10.0 mmol/L | FPG:7.8~10.0 mmol/L,2 hPG或随机血糖7.8~13.9 mmol/L |
2022 ADA/AACE共识[ | 随机血糖6.1~7.8 mmol/L | 随机血糖10.0~13.9 mmol/L | 随机血糖7.8~10.0 mmol/L | 随机血糖10~13.9 mmol/L | 临终关怀者超过13.9 mmol/L也可接受 |
2021-2022 JBDS-IP指南[ | 随机血糖6.0~12.0 mmol/L | 随机血糖6.0~12.0 mmol/L,妊娠状态随机血糖5.0~8.0 mmol/L | 随机血糖6.0~10.0 mmol/L | 随机血糖6.0~12.0 mmol/L,临终关怀者6.0~15.0 mmol/L |
Table 1 Glycemic targets in non-pregnant,non-surgical and non-emergency hospitalized patients
文献 | 年轻的新诊断的糖尿病患者和低血糖风险小的患者 | 低血糖高危患者a | 使用糖皮质激素患者 | 重症监护室(ICU)非重症患者 | 特殊情况b |
---|---|---|---|---|---|
2017中国住院患者血糖管理专家共识[ | FPG:4.4~6.1 mmol/L,2 hPG或随机血糖6.1~7.8 mmol/L | FPG:7.8~10.0 mmol/L,2 hPG或随机血糖7.8~13.9 mmol/L | FPG:6.1~7.8 mmol/L,2 hPG或随机血糖,7.8~10.0 mmol/L | FPG:6.1~7.8 mmol/L,2 hPG或随机血糖7.8~10.0 mmol/L | FPG:7.8~10.0 mmol/L,2 hPG或随机血糖7.8~13.9 mmol/L |
2022 ADA/AACE共识[ | 随机血糖6.1~7.8 mmol/L | 随机血糖10.0~13.9 mmol/L | 随机血糖7.8~10.0 mmol/L | 随机血糖10~13.9 mmol/L | 临终关怀者超过13.9 mmol/L也可接受 |
2021-2022 JBDS-IP指南[ | 随机血糖6.0~12.0 mmol/L | 随机血糖6.0~12.0 mmol/L,妊娠状态随机血糖5.0~8.0 mmol/L | 随机血糖6.0~10.0 mmol/L | 随机血糖6.0~12.0 mmol/L,临终关怀者6.0~15.0 mmol/L |
患者分层 | 空腹及餐前血糖 | 睡前血糖 | 餐后平均血糖 | ||||||
---|---|---|---|---|---|---|---|---|---|
良好 | 中等 | 差 | 良好 | 中等 | 差 | 良好 | 中等 | 差 | |
未使用低血糖风险较高的药物 | 5.0~7.2 | 5.0~8.3 | 5.6~10.0 | 5.0~8.3 | 5.6~10.0 | 6.1~11.1 | <9.8 | <10.5 | <11.4 |
使用低血糖风险较高的药物 | 5.0~8.3 | 5.6~8.3 | 5.6~10.0 | 5.6~10.0 | 5.6~10.0 | 5.6~13.9 | <9.8 | <10.5 | <11.4 |
Table 2 Glycemic targets in elderly inpatients with diabetes
患者分层 | 空腹及餐前血糖 | 睡前血糖 | 餐后平均血糖 | ||||||
---|---|---|---|---|---|---|---|---|---|
良好 | 中等 | 差 | 良好 | 中等 | 差 | 良好 | 中等 | 差 | |
未使用低血糖风险较高的药物 | 5.0~7.2 | 5.0~8.3 | 5.6~10.0 | 5.0~8.3 | 5.6~10.0 | 6.1~11.1 | <9.8 | <10.5 | <11.4 |
使用低血糖风险较高的药物 | 5.0~8.3 | 5.6~8.3 | 5.6~10.0 | 5.6~10.0 | 5.6~10.0 | 5.6~13.9 | <9.8 | <10.5 | <11.4 |
指南 | 2020围术期血糖管理专家共识[ | 2021成人围手术期血糖监测专家共识[ | 2022 ADA共识[ |
---|---|---|---|
血糖管理目标 | 术前随机血糖:6.0~12.0 mmol/L,HbA1c<8.5%,围术期血糖:7.8~10.0 mmol/L。 术后正常进食:餐前血糖≤7.8 mmol/L,餐后血糖≤10.0 mmol/L,随机血糖6.1~10.0 mmol/L;部分患者血糖目标上限放宽至13.9 mmol/L | 普通手术:HbA1c<8.5%,空腹或餐前血糖8.0~10.0 mmol/L,2 hPG 8.0~12.0 mmol/L,短期随机血糖<15.0 mmol/L也可接受 精细手术:空腹或餐前血糖4.4~6.0 mmol/L,2 hPG或随机血糖6.0~8.0 mmol/L 器官移植手术、身体状况良好、无脑心血管并发症风险的非老年患者或应激性高血糖:空腹或餐前血糖6.0~8.0 mmol/L,2 hPG或随机血糖8.0~10.0 mmol/L | 随机血糖:4.4~10.0mmo/l |
Table 3 Glycemic targets in the perioperative period
指南 | 2020围术期血糖管理专家共识[ | 2021成人围手术期血糖监测专家共识[ | 2022 ADA共识[ |
---|---|---|---|
血糖管理目标 | 术前随机血糖:6.0~12.0 mmol/L,HbA1c<8.5%,围术期血糖:7.8~10.0 mmol/L。 术后正常进食:餐前血糖≤7.8 mmol/L,餐后血糖≤10.0 mmol/L,随机血糖6.1~10.0 mmol/L;部分患者血糖目标上限放宽至13.9 mmol/L | 普通手术:HbA1c<8.5%,空腹或餐前血糖8.0~10.0 mmol/L,2 hPG 8.0~12.0 mmol/L,短期随机血糖<15.0 mmol/L也可接受 精细手术:空腹或餐前血糖4.4~6.0 mmol/L,2 hPG或随机血糖6.0~8.0 mmol/L 器官移植手术、身体状况良好、无脑心血管并发症风险的非老年患者或应激性高血糖:空腹或餐前血糖6.0~8.0 mmol/L,2 hPG或随机血糖8.0~10.0 mmol/L | 随机血糖:4.4~10.0mmo/l |
项目 | 2017中国住院患者血糖管理专家共识[ | 2022 ADA共识[ | 2021 JBDS-IP指南[ | 2015 NICE指南[ |
---|---|---|---|---|
妊娠糖尿病 | 餐前血糖≤5.3 mmol/L,夜间血糖>3.3 mmol/L,1 hPG≤7.8 mmol/L,2 hPG≤6.7 mmol/L,HbA1c <5.5% | FPG 3.9~5.3 mmol/L,1 hPG 6.1~7.8 mmol/L,2 hPG 5.6~6.7 mmol/L,HbA1c<6.0%,必要时可放宽至<7.0% | 分娩及分娩期间随机血糖4.0~7.0 mmol/L,可放宽至5.0~8.0 mmol/L,分娩后随机血糖6.0~10.0 mmol/L,母乳喂养前及睡前血糖>6.0 mmol/L | 餐前血糖≤5.3 mmol/L,1 hPG≤7.8 mmol/L,2 hPG≤6.4 mmol/L |
糖尿病合并妊娠 | 餐前、夜间及空腹血糖:3.3~5.6 mmol/L;餐后峰值血糖:5.6~7.1 mmol/L,HbA1c<6.0% | 与妊娠糖尿病一致 | 与妊娠糖尿病一致 | 与妊娠糖尿病一致 |
Table 4 Glycemic targets in hospitalized pregnant patients
项目 | 2017中国住院患者血糖管理专家共识[ | 2022 ADA共识[ | 2021 JBDS-IP指南[ | 2015 NICE指南[ |
---|---|---|---|---|
妊娠糖尿病 | 餐前血糖≤5.3 mmol/L,夜间血糖>3.3 mmol/L,1 hPG≤7.8 mmol/L,2 hPG≤6.7 mmol/L,HbA1c <5.5% | FPG 3.9~5.3 mmol/L,1 hPG 6.1~7.8 mmol/L,2 hPG 5.6~6.7 mmol/L,HbA1c<6.0%,必要时可放宽至<7.0% | 分娩及分娩期间随机血糖4.0~7.0 mmol/L,可放宽至5.0~8.0 mmol/L,分娩后随机血糖6.0~10.0 mmol/L,母乳喂养前及睡前血糖>6.0 mmol/L | 餐前血糖≤5.3 mmol/L,1 hPG≤7.8 mmol/L,2 hPG≤6.4 mmol/L |
糖尿病合并妊娠 | 餐前、夜间及空腹血糖:3.3~5.6 mmol/L;餐后峰值血糖:5.6~7.1 mmol/L,HbA1c<6.0% | 与妊娠糖尿病一致 | 与妊娠糖尿病一致 | 与妊娠糖尿病一致 |
患儿不同状态 | 血糖控制目标 |
---|---|
非手术、非重症患儿 | 随机血糖4.0~7.0 mmol/L,2 hPG或不能进食时随机血糖5.0~10.0 mmol/L |
围术期患儿 | 随机血糖5.0~10.0 mmol/L |
肠内或肠外营养患儿 | 随机血糖7.8~10.0 mmol/L |
使用糖皮质激素患儿 | FPG或餐前血糖4.0~7.0 mmol/L,2 hPG或不能进食时随机血糖5.0~10.0 mmol/L |
重症患儿 | 随机血糖5.0~10.0 mmol/L |
肿瘤患儿 | 个体化设定 |
Table 5 Glycemic targets in hospitalized children and adolescents with special conditions
患儿不同状态 | 血糖控制目标 |
---|---|
非手术、非重症患儿 | 随机血糖4.0~7.0 mmol/L,2 hPG或不能进食时随机血糖5.0~10.0 mmol/L |
围术期患儿 | 随机血糖5.0~10.0 mmol/L |
肠内或肠外营养患儿 | 随机血糖7.8~10.0 mmol/L |
使用糖皮质激素患儿 | FPG或餐前血糖4.0~7.0 mmol/L,2 hPG或不能进食时随机血糖5.0~10.0 mmol/L |
重症患儿 | 随机血糖5.0~10.0 mmol/L |
肿瘤患儿 | 个体化设定 |
[1] |
|
[2] |
翁建平. 广东省住院病人糖尿病调查[J]. 中华医学杂志,2006,86(12):815-818.
|
[3] |
|
[4] |
|
[5] |
|
[6] |
AMERICAN DIABETES ASSOCIATION. Executive summary:standards of medical care in diabetes—2012[J]. Diabetes Care,2012,35(Suppl 1):S4-10. DOI:10.2337/dc12-s004.
|
[7] |
中国医师协会内分泌代谢科医师分会,中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志,2017,33(1):1-10. DOI:10.3760/cma.j.issn.1000-6699.2017.01.001.
|
[8] |
陈玉凤. 南京市区三甲医院住院患者血糖管理多中心调查[D]. 南京:南京中医药大学,2015.
|
[9] |
付丽媛,马建华,丁波,等. 非内分泌专科住院患者2020例糖代谢状况调查[J]. 中华糖尿病杂志,2012,4(5):279-281.
|
[10] |
纪涛,刘随意,翟骁,等. 住院医生血糖管理能力的调查分析[J]. 第二军医大学学报,2014,35(9):1020-1023.
|
[11] |
|
[12] |
|
[13] |
American Diabetes Association Professional Practice Committee. Standards of Medical Carein Diabetes-2022[J]. Diabetes Care,2022,45(Suppl 1). DOI:10.2337/dc22-S015.
|
[14] |
Joint British Diabetes Societies for Inpatient Care. The hospital management of hypoglycaemia in adults with diabetes mellitus. Revised [EB/OL]. (2021-04) [2022-01-10].
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
UK Prospective Diabetes Study(UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34)[J]. Lancet,1998,352:854-865.
|
[20] |
UK Prospective Diabetes Study(UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33)[J]. Lancet,1998,352:837-853.
|
[21] |
|
[22] |
Nice-Sugar Study Investigators,
|
[23] |
|
[24] |
Joint British Diabetes Societies (JBDS) for Inpatient Care Group.Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy [EB/OL].[2023-01-10].
|
[25] |
Advance Collaborative Group,
|
[26] |
国家老年医学中心,中华医学会老年医学分会,中国老年保健协会糖尿病专业委员会.中国老年糖尿病诊疗指南(2021年版)[J].中华糖尿病杂志,2021,13(1):14-46.
|
[27] |
|
[28] |
|
[29] |
Joint British Diabetes Societies(JBDS) for Inpatient Care Group.Management of adults with diabetes on dialysis [EB/OL].(2021-03)[2022-01-10].
|
[30] |
Joint British Diabetes Societies(JBDS) for Inpatient Care Group. Guideline for Perioperative Care for People with Diabetes Mellitus Undergoing Elective and Emergency Surgery[EB/OL].(2021-03)[2022-01-10].
|
[31] |
高卉,黄宇光,许力,等.围术期血糖管理专家共识(2020版)[EB/OL].(2021-07-05)[2022-01-10].
|
[32] |
|
[33] |
|
[34] |
陈莉明,陈伟,陈燕燕,等. 成人围手术期血糖监测专家共识[J]. 中国糖尿病杂志,2021,29(2):81-85.
|
[35] |
|
[36] |
National Collaborating Centre for Women's and Children's Health (UK). Diabetes in Pregnancy:Management of Diabetes and Its Complications from Preconception to the Postnatal Period[M]. London:National Institute for Health and Care Excellence(UK),2015.
|
[37] |
|
[38] |
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
中国医师协会儿科学分会内分泌遗传代谢学组,中华医学会儿科学分会急救学组.儿童及青少年特殊情况下住院高血糖管理指导建议[J].中华糖尿病杂志,2020,12(10):765-771.
|
[44] |
American Diabetes Association. 13. children and adolescents:Standards of medical care in diabetes—2021[J]. Diabetes Care,2021,44(Suppl 1):S180-199. DOI:10.2337/dc21-S013.
|
[45] |
中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2021年版)[J].中华糖尿病杂志,2021,13(10):936-948. DOI:10.3760/cma.j.cn115791-20210810-00436.
|
[46] |
|
[47] |
|
[1] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[2] | CHEN Yanyan, SHI Min, WANG Yi, FU Jianfang, ZHANG Ying, LIU Xiangyang, ZHANG Weiqing, TA Shengjun, LIU Liwen, LI Zeping, ZHOU Jie, LI Xiaomiao. Correlation between Subclinical Left Ventricular Systolic Function and Diabetic Microvascular Complications in Patients with Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(35): 4412-4418. |
[3] | LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307. |
[4] | YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295. |
[5] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[6] | ZHANG Juan, LI Haifen, LI Xiaoman, YAO Miao, MA Huizhen, MA Qiang. Construction of Recurrence Risk Prediction Model for Diabetic Foot Ulcer on the Basis of Logistic Regression, Support Vector Machine and BP Neural Network Model [J]. Chinese General Practice, 2023, 26(32): 4013-4019. |
[7] | CHENG Jingwei, QIAO Junjun, YIN Zhen, HU Junpeng, WANG Qinghe, LIU Yangqing, WANG Yanfang. Interpretation of ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in Children and Adolescents with Diabetes [J]. Chinese General Practice, 2023, 26(30): 3719-3724. |
[8] | ZHOU Xiaoqi, LIU Xinhui, ZHANG Wei, LI Changfeng, YAN Yaqiong. Association of Alanine Transaminase and Aspartate Aminotransferase/Alanine Transaminase Ratio with Type 2 Diabetes and Metabolic Syndrome in the Elderly [J]. Chinese General Practice, 2023, 26(29): 3645-3649. |
[9] | ZHAO Xiaohua, DU Lin, GAO Shengnan, JIANG Ziyun. Multiple Deep Muscle Abscesses in Type 2 Diabetes in the Elderly: Report of One Case and Literature Review [J]. Chinese General Practice, 2023, 26(29): 3715-3718. |
[10] | CHENG Xiaoran, ZHANG Xiaotian, LI Mingyue, CHENG Haozhe, TANG Haoqing, ZHENG Huixian, ZHANG Baisong, LIU Xiaoyun. Impact of Chronic Diseases Follow-up on Health Behaviors and Blood Pressure/Glucose Control of Patients with Hypertension and Diabetes in the Context of Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(28): 3482-3488. |
[11] | LUO Dan, XU Jingjing, WANG Yubing, LI Mingzi, FORBES Angus. Development and Preliminary Practice of Resilience-oriented Structured Treatment and Educational Program for Adolescents with Type 1 Diabetes [J]. Chinese General Practice, 2023, 26(27): 3423-3429. |
[12] | DONG Yanan, JIANG Xiaorui, WANG Kai, ZONG Chuanchong, LIN Guodong, LI Xiangqing, LIN Chunxiao, CHI Juntao. The Effect of Modified Tibial Transverse Transport Technique in the Treatment of Wagner Grade Ⅲ and Ⅳ Diabetic Foot Patients [J]. Chinese General Practice, 2023, 26(27): 3411-3416. |
[13] | CHEN Lunwen, ZHOU Yang, YAN Guodong, SHEN Yi, SUN Chen, CAI Wanli, CHU Minjie, XIAO Jing. Risk of Malignant Tumor in Patients with Type 2 Diabetes: a Prospective Population-based Study [J]. Chinese General Practice, 2023, 26(26): 3238-3245. |
[14] | FEI Sijie, ZHANG Qiang, LIU Fangfang, BAI Lu, SUN Caihong, XIN Caifeng. Correlation between Glycated Hemoglobin Variability and New-onset Atrial Fibrillation in Type 2 Diabetes Patients Combined with Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2023, 26(26): 3246-3251. |
[15] | LU Zuowei, CAO Hongwei, LIU Tao, ZHANG Nana, CHEN Yanyan, SHI Qinli, LIU Xiangyang, WANG Qiong, LAI Jingbo, LI Xiaomiao. Development and Validation of a Risk Prediction Model for the Progression from Microalbuminuria to Macroalbuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(26): 3259-3268. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||